Hedge funds cut NFLX, keep big bets on MSFT, AMZN, add NVDA
William Richard White, Chief Financial Officer of Akero Therapeutics, Inc. (NASDAQ:AKRO), sold 1,634 shares of common stock on June 18, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at prices ranging from $54.33 to $54.84, for a total value of $89,608. The transaction occurred as the stock trades near its 52-week high of $58.40, having delivered an impressive 133% return over the past year. According to InvestingPro analysis, the stock appears slightly overvalued at current levels.
Following the transaction, White directly owns 57,521 shares of Akero Therapeutics.
The sale was to cover tax withholding obligations related to the vesting of restricted stock units, according to the filing. The sales were automatic under a "sell-to-cover" policy adopted by Akero Therapeutics.
In other recent news, Akero Therapeutics has reported promising results from its Phase 2b SYMMETRY trial, highlighting the potential of its drug efruxifermin (EFX) in treating liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis (MASH). The trial results, published in the New England Journal of Medicine, showed significant improvements in fibrosis without worsening MASH in the treatment groups compared to placebo. Additionally, Akero’s financial position remains strong, with $1.1 billion in cash reserves, expected to support operations into 2028. Analysts have been actively revising their outlooks on Akero, with Citi reducing its price target to $78 while maintaining a Buy rating, and Morgan Stanley (NYSE:MS) adjusting its target to $84, also keeping an Overweight rating. Jefferies continues to support Akero with a Buy rating and a $75 price target, emphasizing the robust data from Akero’s FGF21 therapy. Meanwhile, Clear Street initiated coverage with a Buy rating and a $49 target, citing the strong potential of EFX in treating NASH. These developments follow Akero’s presentation of data at the European Association for the Study of the Liver conference, further solidifying its position in the biotechnology sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.